

PRESS RELEASE

Chandler, September 7th, 2010:

New Test for Coronary Artery Disease Now Available at Warner Family Practice

Blood-Based Gene Expression Test Assesses Presence of Obstructive Coronary Artery Disease

Warner Family Practice today announced the availability of Corus™ CAD, the first and only clinically validated blood-based test for obstructiveⁱ coronary artery disease in non-diabetic patients with stable chest pain.

Warner Family Practice is among the first institutions in the country to offer this test to patients with suspected obstructive coronary artery disease.

Corus CAD is a safe and convenient gene expression test that provides unique biological insight into a patient's coronary artery disease status at the molecular and cellular level. The test requires only a simple blood draw and does not expose patients to risks of radiation or imaging agent intolerance. By combining this information with standard clinical assessments, clinicians can obtain a more complete picture of their patient's disease state and, as a result, better individualize care.

"Corus CAD gives me a clinically proven way to obtain objective information that helps in the evaluation of the best path forward for an individual with stable chest pain – increasing my confidence in sometimes difficult decisions and providing added reassurance to the patient," said Merle Turner, D.O.

"I've had chest pain for the past few years, and of course the possibility of a heart attack was a major concern for me," said Janna Pace, one of Dr. Turner's patients. "I was very relieved to receive the results of the Corus CAD test. It gave me a lot of comfort to know that my chest pain was not likely to be caused by obstructive coronary artery disease."

About Corus CAD

Corus CAD, developed by CardioDx, Inc., of Palo Alto, Calif., (www.cardiodx.com), is the first and only blood-based test for obstructive coronary artery disease. The test involves a routine blood draw conveniently administered in the clinician's office and does not expose patients to risks of radiation or imaging agent intolerance. Clinically validated in a U.S. prospective, multi-center trial called PREDICT (Personalized Risk Evaluation and Diagnosis in the Coronary Tree), Corus CAD is a decision-making tool that can help primary care physicians and cardiologists evaluate whether a non-diabetic patient's symptoms are due to obstructive coronary artery disease. It is the first sex-specific test for obstructive coronary artery disease, accounting for critical biological differences between men and women.

Corus CAD measures the RNA levels of 23 genes. Because the RNA levels are increased or decreased when obstructive coronary artery disease is present, Corus CAD is able to measure the likelihood that an individual patient has obstructive coronary artery disease from a simple blood sample.

About Gene Expression Testing

Gene expression testing provides valuable tissue and cell-specific information about the molecular mechanisms involved in disease processes, enabling evaluation of an individual patient's disease state, activity, and/or progression at a given point in time. Unlike genetic tests, which measure genetic variations, mutations, traits and predispositions – factors that are constant over a person's lifetime – gene expression testing assesses a dynamic process, integrating both genetic predisposition and additional behavioral and environmental influences on current disease state.

About Obstructive Coronary Artery Disease

Cardiovascular disease affects tens of millions of Americans each year and is the leading cause of death in the United States. Coronary artery disease is a narrowing or blockage of the coronary arteries (the major blood vessels that supply the heart with blood, oxygen and nutrients) that reduces blood flow to the heart muscle. As a result of the blockage, the heart does not get enough oxygenated blood, which can often cause chest pain (angina), shortness of breath and other symptoms. A severe blockage can cause a heart attack (myocardial infarction) or even death; one of every five deaths among Americans is caused by coronary artery disease.

About Warner Family Practice

Dr. Merle Turner started his practice in 1983. His vision for the future and dedication to his patients and their health has enabled him to grow from a solo family practice to a world-class medical facility. Setting the standard for heart attack and stroke prevention, the exceptional providers of Warner's elite practice supplement world class technology with a holistic lifestyle assessment to educate and change the fundamentals of their patients'

lifestyle that contribute to these preventable diseases. They cater to being able to care for every generation from infants to grandparents.

#

(i) Obstructive CAD is defined as at least one atherosclerotic plaque causing greater than or equal to 50% luminal diameter stenosis in a major coronary artery (greater than or equal to 1.5mm lumen diameter) as determined by invasive quantitative coronary angiography (QCA).